DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2018 to Q4 2025

Type / Class
Equity / Voting Common Shares, no par value
Symbol
DMAC on Nasdaq
Shares outstanding
52,272,727
Price per share
$8.53
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
12,053,996
Total reported value
$95,986,433
% of total 13F portfolios
0%
Share change
-796,042
Value change
-$5,768,433
Number of holders
92
Price from insider filings
$8.53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TRILL AB 17% +13% $70,252,906 +$8,447,765 8,825,742 +14% TRILL AB 31 Dec 2025
TomEnterprise AB 16% $32,695,950 8,383,577 TomEnterprise AB 23 Jul 2025
JACINTO RICHARD II 9.6% $34,067,114 4,958,823 Richard Jacinto II 30 Sep 2025
COOPERMAN LEON G 6.6% +5% $28,462,500 +$1,486,972 3,450,000 +5.5% Cooperman Leon G. 31 Dec 2025

As of 31 Dec 2025, 92 institutional investors reported holding 12,053,996 shares of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC). This represents 23% of the company’s total 52,272,727 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) together control 21% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
COOPERMAN LEON G 3.9% 2,020,000 -38% 0.53% $16,079,200
BlackRock, Inc. 3.6% 1,900,899 +13% 0% $15,131,156
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 1.7% 875,000 0% 14% $6,965,000
MILLENNIUM MANAGEMENT LLC 1.5% 768,560 -35% 0% $6,117,738
GEODE CAPITAL MANAGEMENT, LLC 1.5% 764,255 +7.4% 0% $6,084,946
VANGUARD GROUP INC 1.4% 723,120 +8.8% 0% $5,756,035
STATE STREET CORP 1.2% 627,771 +32% 0% $4,997,057
MORGAN STANLEY 1% 547,610 -5.5% 0% $4,358,976
FIRST MANHATTAN CO. LLC. 0.77% 405,000 -20% 0.01% $3,223,800
Bleichroeder LP 0.73% 382,317 0% 0.54% $3,043,243
NORTHERN TRUST CORP 0.62% 325,527 -4.1% 0% $2,591,196
OSAIC HOLDINGS, INC. 0.47% 246,972 +35% 0% $1,965,893
LPL Financial LLC 0.38% 197,150 -3% 0% $1,569,314
GOLDMAN SACHS GROUP INC 0.25% 129,388 +67% 0% $1,029,928
Bank of New York Mellon Corp 0.23% 120,977 +75% 0% $962,973
Nuveen, LLC 0.21% 111,028 +49% 0% $883,783
CITADEL ADVISORS LLC 0.21% 110,737 +60% 0% $881,467
WELLINGTON MANAGEMENT GROUP LLP 0.2% 103,704 0% $825,484
MEMBERS WEALTH LLC 0.19% 101,382 0.54% $864,282
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.19% 96,880 +4.8% 0% $771,165
Kalehua Capital Management LLC 0.18% 95,359 0% 0.77% $759,058
Informed Momentum Co LLC 0.17% 91,425 0.08% $727,743
FRED ALGER MANAGEMENT, LLC 0.16% 83,137 0% $661,771
MAGNOLIA CAPITAL ADVISORS LLC 0.15% 77,405 +674% 0.13% $616,144
Blue Trust, Inc. 0.13% 69,122 0% 0.01% $550,211

Institutional Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 12,053,996 $95,986,433 -$5,768,433 $7.96 92
2025 Q3 12,754,591 $82,807,935 +$25,371,563 $6.87 77
2025 Q2 8,764,697 $34,183,334 +$4,951,594 $3.90 58
2025 Q1 7,514,092 $28,477,666 +$2,854,596 $3.79 57
2024 Q4 6,729,012 $36,539,618 +$6,248,431 $5.43 45
2024 Q3 5,580,411 $23,326,555 +$2,250,136 $4.19 40
2024 Q2 5,062,392 $14,934,296 +$1,369,212 $2.95 32
2024 Q1 4,598,019 $12,730,274 +$2,073,072 $2.77 31
2023 Q4 3,840,738 $10,907,609 -$629,214 $2.84 37
2023 Q3 4,250,465 $10,966,479 +$1,920,978 $2.58 35
2023 Q2 3,490,534 $15,080,277 +$4,150,477 $4.32 30
2023 Q1 2,565,385 $3,924,875 +$61,558 $1.53 22
2022 Q4 2,524,139 $3,989,530 -$6,541 $1.58 27
2022 Q3 2,527,104 $3,132,035 -$2,355,232 $1.24 23
2022 Q2 3,668,922 $7,411,731 -$802,498 $2.02 24
2022 Q1 4,006,054 $10,017,522 -$427,839 $2.50 28
2021 Q4 3,993,298 $14,891,858 +$4,430,787 $3.73 34
2021 Q3 2,804,345 $11,247,922 -$4,241,878 $4.01 31
2021 Q2 3,783,974 $16,902,446 -$48,644,584 $4.45 38
2021 Q1 5,694,347 $88,119,211 +$33,217,401 $9.15 38
2020 Q4 5,983,974 $60,607,941 +$30,865 $10.14 34
2020 Q3 6,707,026 $28,383,192 +$15,491,837 $4.24 30
2020 Q2 3,034,327 $21,027,519 +$1,227,002 $6.93 20
2020 Q1 2,928,881 $8,241,240 +$5,983,161 $2.80 18
2019 Q4 806,746 $3,914,130 -$398,177 $4.85 13
2019 Q3 956,852 $1,976,000 -$928,156 $2.07 14
2019 Q2 1,283,324 $6,365,000 +$1,445,583 $4.96 14
2019 Q1 1,013,152 $4,601,000 +$283,018 $4.54 10
2018 Q4 1,032,562 $3,003,000 +$3,003,000 $2.91 7